IRIS Accounts Production v25.2.0.378 15910531 director 21.8.24 31.8.25 31.8.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh159105312024-08-20159105312025-08-31159105312024-08-212025-08-31159105312024-08-2015910531ns15:EnglandWales2024-08-212025-08-3115910531ns14:PoundSterling2024-08-212025-08-3115910531ns10:Director12024-08-212025-08-3115910531ns10:PrivateLimitedCompanyLtd2024-08-212025-08-3115910531ns10:SmallEntities2024-08-212025-08-3115910531ns10:AuditExempt-NoAccountantsReport2024-08-212025-08-3115910531ns10:SmallCompaniesRegimeForDirectorsReport2024-08-212025-08-3115910531ns10:SmallCompaniesRegimeForAccounts2024-08-212025-08-3115910531ns10:FullAccounts2024-08-212025-08-3115910531ns10:RegisteredOffice2024-08-212025-08-3115910531ns5:RetainedEarningsAccumulatedLosses2025-08-31
REGISTERED NUMBER: 15910531 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD

21 AUGUST 2024 TO 31 AUGUST 2025

FOR

B12 LABORATORY SOLUTIONS LIMITED

B12 LABORATORY SOLUTIONS LIMITED (REGISTERED NUMBER: 15910531)

CONTENTS OF THE FINANCIAL STATEMENTS
for the period 21 August 2024 to 31 August 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


B12 LABORATORY SOLUTIONS LIMITED

COMPANY INFORMATION
for the period 21 August 2024 to 31 August 2025







DIRECTOR: M J Warren





REGISTERED OFFICE: 78 The Street Kingston
Canterbury
United Kingdom
CT4 6JQ





REGISTERED NUMBER: 15910531 (England and Wales)





ACCOUNTANTS: Magma Audit LLP
16 Davy Court
Castle Mound Way
Rugby, CV23 0UZ
Magma Audit LLP is part
Of the Dains Group

B12 LABORATORY SOLUTIONS LIMITED (REGISTERED NUMBER: 15910531)

BALANCE SHEET
31 August 2025

£   
CURRENT ASSETS
Cash in hand 1
TOTAL ASSETS LESS CURRENT
LIABILITIES

1

RESERVES
Retained earnings 1
1

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 August 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 August 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 1 December 2025 and were signed by:





M J Warren - Director


B12 LABORATORY SOLUTIONS LIMITED (REGISTERED NUMBER: 15910531)

NOTES TO THE FINANCIAL STATEMENTS
for the period 21 August 2024 to 31 August 2025


1. STATUTORY INFORMATION

B12 Laboratory Solutions Limited is a limited company, registered in England and Wales. Its registered office address is 78 The Street Kingston, Canterbury, United Kingdom, CT4 6JQ and the registered number is 15910531.

The presentation currency of the financial statements is pound sterling (£) and the figures are rounded to the nearest £1.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial instruments
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation
The tax expense for the year comprises current and deferred tax.

Tax is recognised in profit or loss except that a change attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:
- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Both current and deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Cash and cash equivalents
Cash and cash equivalents are represented by cash in hand, deposits held at call with financial institutions, and other short-term highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 .